IP Library Granted Patent US 11,845,755
Granted Patent B2
US 11,845,755 · App. 18/117,913 · Granted Dec 19, 2023

Compounds and methods for treatment of viral infections

Inventors: Mark J. Bartlett (Castro Valley, CA); Daniel H. Byun (Foster City, CA); Yifan Deng (Milpitas, CA); Jennifer L. Cosman Ellis (Foster City, CA); Rao V. Kalla (Cupertino, CA); Richard L. Mackman (Millbrae, CA); Dustin S. Siegel (Half Moon Bay, CA); Xianhuang Zeng (Redwood City, CA)
Assignee: Gilead Sciences, Inc.
C07D487/04A61K9/0053A61K45/06A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,845,755
App. No.
18/117,913
Granted
Dec 19, 2023
Kind
B2
Abstract

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Claims (17)

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical formulation is for oral administration.

4. A method of treating a coronavirus infection in a human in need thereof, wherein the method comprises administering to the human the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered to the human via oral administration.

6. The method of claim 4 , wherein the method comprises administering to the human at least one additional therapeutic or prophylactic agent.

7. The method claim 4 , wherein the coronavirus infection is a zoonotic coronavirus infection.

8. The method of claim 4 , wherein the coronavirus infection is a SARS-CoV-2 infection.

9. A compound of Formula:

10. A pharmaceutical composition comprising the compound of claim 9 and one or more pharmaceutically acceptable excipients.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical formulation is for oral administration.

12. A method of treating a coronavirus infection in a human in need thereof, wherein the method comprises administering to the human the compound of claim 9 .

13. The method of claim 12 , wherein the compound is administered to the human via oral administration.

14. The method of claim 12 , wherein the method comprises administering to the human at least one additional therapeutic or prophylactic agent.

15. The method of claim 12 , wherein the coronavirus infection is a zoonotic coronavirus infection.

16. The method of claim 12 , wherein the coronavirus infection is a SARS-CoV-2 infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: BARTLETT, MARK J.; BYUN, DANIEL H.; DENG, YIFAN; COSMAN ELLIS, JENNIFER L.; KALLA, RAO V.; MACKMAN, RICHARD L.; SIEGEL, DUSTIN S.; ZENG, XIANHUANG
To: GILEAD SCIENCES, INC.
Reel/Frame 063664/0422 →
Continuity (6)
Continuation 18115955 · Mar 1, 2023
Provisional Application 63434993 · Dec 23, 2022
Provisional Application 63424083 · Nov 9, 2022
Provisional Application 63390421 · Jul 19, 2022
Provisional Application 63315769 · Mar 2, 2022
Related Publication 20230279015A1 · Sep 7, 2023
Cited By (6)
US 12,297,226 US 12,357,577 US 12,404,289 US 12,509,466 US 12,655,172 US 12,723,057